Springer Nature publishes scientific journals, books and the Nature-branded research titles, and sells the subscriptions and open-access fees that fund them, so its revenue is tied to the volume of academic research being published and read. The moat is the brand and editorial filter of titles like Nature and Scientific Reports, which keep authors and institutional library customers locked in, and gross margin of 87% reflects how little it costs to deliver an extra article. The growth lever is the shift from subscription to open-access and the rising share of publishing revenue from article processing charges, though reported revenue growth of 3.0% says that shift is still a slow grind. What makes it worth a look now is the valuation: a trailing P/E of 12.4 and forward P/E of 11.3 against a 20.1% operating margin and 17.1% ROE, for a business that converts most sales into cash. The open questions are whether library budgets and funder policies keep pace with research output and whether 3% growth is the ceiling, which the research process should settle.
Plain-English pros, cons, and what to watch. Pro feature.
See what each model says, the assumptions behind it, the bad, normal and good cases, and why the fair value changed.
The full quality picture: a reason under every score, how the scores moved, and the conviction breakdown.
The full analyst picture: the price-target distribution against the current price, forward consensus estimates, and how ACCE's own models compare.
Trades are only made public after a delay. We show the delay so you know how old the news is.
Follow the informed money: 13F position changes, insider and Congress trades, and 13D activist filings.
| Date | Type | New | Previous | Price |
|---|---|---|---|---|
| 23 Oct 2026, 01:53 CEST | ACCE price target | €24.00 | first publication | €20.65 |
| 22 Oct 2026, 13:04 CEST | Fair value | €21.73 | first publication | €20.50 |
| 22 Oct 2026, 13:04 CEST | Rating | Fairly valued | first publication | €20.50 |
Answered from Springer Nature AG & Co. KGaA fundamentals + recent valuations. Every number shows its source and date.
| Company | Price | Fair value | vs fair value | P/E | ROE | Quality | Score |
|---|---|---|---|---|---|---|---|
| SPG.DE Springer Nature AG & Co. KGaA | €20.80 | €22 | 4% below | 12.5x | 17.1% | 79 | 57 |
| 9468.T Kadokawa Corporation | ¥3806.00 | - | - | - | - | 49 | 49 |
| WLYB John Wiley & Sons Inc. Common Stock | $54.08 | $41 | 31% above | 14.6x | 25.9% | 73 | 73 |
| WLY John Wiley & Sons Inc. Common Stock | $54.05 | $46 | 17% above | 14.5x | 25.9% | 73 | 72 |
| TXGN.SW TX Group AG | CHF 184.60 | CHF 104 | 78% above | - | 0.7% | 51 | 62 |
| PSO Pearson Plc Common Stock | $18.39 | $15 | 23% above | 27.2x | 9.2% | 63 | 62 |
| PSON.L Pearson plc | £13.71 | £10 | 31% above | 27.4x | 9.2% | 63 | 64 |
Where SPG.DE ranks against its sector peers on each metric.